Uterine Cancer
Conditions
Keywords
Uterine Cancer
Brief summary
Clinical study participation has historically been heavily biased toward specific demographics. Several people will be invited to enroll in this trial so that it may collect a variety of data about uterine cancer clinical study experiences and identify barriers to participation as well as the causes of participants' failure or withdrawal. People with uterine cancer who are invited to take part in medical study will benefit from the analysis of the data.
Interventions
None listed
Sponsors
Power Life Sciences Inc.
Study design
Observational model
CASE_CROSSOVER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed * Diagnosis of uterine cancer * No prior treatment for uterine cancer
Exclusion criteria
* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial * Enrolled in another research study * Inability to provide written informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of patients who decide to enroll in a uterine cancer clinical research | 3 months |
| Rate of patients who remain in a uterine cancer clinical trial to trial completion | 12 months |
Countries
United States
Contacts
Primary ContactMichael B Gill
Outcome results
None listed